title: [Update of clinical programs using hadrontherapy 2008-2012].
abstract: Hadrontherapy, a type of radiation therapy dealing with heavy charged particles, has become for the past decade one of the most sophisticated and attractive approach in the management of cancer. This is related with major technological innovations that have made available, at a relatively cheap cost, compact proton accelerators equipped with rotational gantries. The implementation of pencil beam scanning should also make treatment planning and delivery much easier and faster than conventional approaches. Until now, approximately 100,000 patients have been treated with protons worldwide. Due to more complex technological and biological challenges, light ion therapy - mainly carbon ions - has developed at a lower pace, except in Japan where most of the 15,000 treated patients have been enrolled. Current indications for protons include firstly, locally aggressive tumours non or incompletely resected, that are located close to critical normal structures: ocular melanomas, skull base and spinal canal low grade sarcomas, selected ENT carcinomas (like adenoid cystic); secondly, improvement of tolerance to radiations: delayed, mainly in paediatric malignancies, due to the exquisite sensitivity of organs under development (including to carcinogenesis); immediate, on bone marrow, mucosae… mainly in concomitant radiation-chemotherapy interactions (tested in esophagus, and lung). Most promising indications for carbon ions include inoperable highly radioresistant primaries, such as mucosal melanomas, high grade bone and soft part sarcomas, and pancreatic carcinomas. Altered fractionations are also of interests that could translate in clinical and economical benefits. Controversies have risen whether more common indications, like prostate, should also be explored.
authors.affiliation: Centre de protonthérapie (ICPO), institut Curie, campus universitaire, bâtiment 101, 15, rue Georges-Clémenceau, 91898 Orsay, France; Centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen, France. Electronic address: jean-louis.habrand@curie.net.
authors.forename: J-L
authors.initials: JL
authors.lastname: Habrand
authors.forename: J
authors.initials: J
authors.lastname: Datchary
authors.forename: C
authors.initials: C
authors.lastname: Alapetite
authors.forename: S
authors.initials: S
authors.lastname: Bolle
authors.forename: V
authors.initials: V
authors.lastname: Calugaru
authors.forename: L
authors.initials: L
authors.lastname: Feuvret
authors.forename: S
authors.initials: S
authors.lastname: Helfre
authors.forename: D
authors.initials: D
authors.lastname: Stefan
authors.forename: S
authors.initials: S
authors.lastname: Delacroix
authors.forename: L
authors.initials: L
authors.lastname: Demarzi
authors.forename: R
authors.initials: R
authors.lastname: Dendale
mesh_terms: D000328:Adult; D002244:Carbon / Q000627:therapeutic use; D002648:Child; D063193:Heavy Ion Radiotherapy / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011836:Radiation Tolerance
chemical_list: D002244:Carbon
keywords: Carbon; Carbone; Clinics; Clinique; Hadrontherapy; Hadronthérapie; Protons; Results; Résultats; Toxicity; Toxicité